关于《维贝格隆治疗膀胱过度活动症：疗效、安全性及患者报告结局的全面综述》的评论 - Suppr

Suppr

超能文献

Comment on: "Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes".

作者信息

Alcántara Montero Antonio

机构信息

Centro de Salud Trujillo, Trujillo, Cáceres, Spain.

出版信息

World J Urol. 2025 Sep 15;43(1):553. doi: 10.1007/s00345-025-05942-5.

DOI:10.1007/s00345-025-05942-5

PMID:40952485

Abstract

摘要

相似文献

Comment on: "Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes".

World J Urol. 2025 Sep 15;43(1):553. doi: 10.1007/s00345-025-05942-5.

Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.

World J Urol. 2025 Aug 26;43(1):514. doi: 10.1007/s00345-025-05799-8.

Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis.

Low Urin Tract Symptoms. 2023 May;15(3):80-88. doi: 10.1111/luts.12475. Epub 2023 Mar 2.

Satisfaction and persistence with vibegron in the first 6 months of overactive bladder treatment: interim results of the phase 4, real-world COMPOSUR study.

BMC Urol. 2025 Apr 2;25(1):66. doi: 10.1186/s12894-025-01742-6.

Comparative Efficacy and Safety of Mirabegron and Vibegron in Female Patients With Overactive Bladder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Urology. 2025 May;199:182-190. doi: 10.1016/j.urology.2025.02.018. Epub 2025 Feb 17.

Comparative efficacy and adverse effects of β3-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis.

Eur J Clin Pharmacol. 2025 Jun 7. doi: 10.1007/s00228-025-03855-1.

Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial () .

BMJ Open. 2025 Mar 24;15(3):e094230. doi: 10.1136/bmjopen-2024-094230.

Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.

Eur Urol Focus. 2022 Jul;8(4):1072-1089. doi: 10.1016/j.euf.2021.08.011. Epub 2021 Sep 22.

Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.

Urology. 2025 Sep 1. doi: 10.1016/j.urology.2025.08.051.

Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study.

Urology. 2023 May;175:67-73. doi: 10.1016/j.urology.2023.02.003. Epub 2023 Feb 22.

本文引用的文献

Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.

World J Urol. 2025 Aug 26;43(1):514. doi: 10.1007/s00345-025-05799-8.

Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.

World J Urol. 2024 Mar 2;42(1):113. doi: 10.1007/s00345-024-04799-4.

Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study.

Urology. 2023 May;175:67-73. doi: 10.1016/j.urology.2023.02.003. Epub 2023 Feb 22.

Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.

Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7. Epub 2021 Jul 8.

Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study.

Curr Med Res Opin. 2018 May;34(5):785-793. doi: 10.1080/03007995.2017.1419170. Epub 2018 Jan 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验